{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:34Z","timestamp":1792788454048,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ygyno.2025.11.016","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:06:12Z","timestamp":1764943572000},"page":"194-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines"],"prefix":"10.1016","volume":"204","author":[{"given":"Rebekah M.","family":"Peplinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse D.","family":"Riordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob L.","family":"Schillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana Pedra","family":"Nobre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin A.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keely K.","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Goodheart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ygyno.2025.11.016_bb0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.016_bb0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/ijgc-2022-003677","article-title":"Novel therapeutics in low-grade serous ovarian cancer","volume":"33","author":"Cobb","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.016_bb0015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/AOG.0000000000001867","article-title":"Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian Cancer","volume":"129","author":"Gockley","year":"2017","journal-title":"Obstet. Gynecol."},{"issue":"9","key":"10.1016\/j.ygyno.2025.11.016_bb0020","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","article-title":"Low-grade serous ovarian cancer: expert consensus report on the state of the science","volume":"33","author":"Grisham","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.016_bb0025","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/ERC-21-0191","article-title":"New therapeutic opportunities for women with low-grade serous ovarian cancer","volume":"29","author":"Moujaber","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2025.11.016_bb0030","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11912-020-00933-8","article-title":"First-line Management of Advanced High-Grade Serous Ovarian Cancer","volume":"22","author":"Mahmood","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"17","key":"10.1016\/j.ygyno.2025.11.016_bb0035","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.34903","article-title":"The highs and lows of serous ovarian cancer","volume":"129","author":"Grisham","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2025.11.016_bb0040","series-title":"National Comprehensive Cancer Network Clinical Practice Guidlines in Oncology for Ovarian Cancer, Version 3.2024","author":"NCCN","year":"2024"},{"issue":"269","key":"10.1016\/j.ygyno.2025.11.016_bb0045","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"issue":"5","key":"10.1016\/j.ygyno.2025.11.016_bb0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"10324","key":"10.1016\/j.ygyno.2025.11.016_bb0055","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ygyno.2025.11.016_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001279","article-title":"Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy","volume":"2","author":"Estep","year":"2007","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.016_bb0065","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13073-021-00952-5","article-title":"Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes","volume":"13","author":"Barnes","year":"2021","journal-title":"Genome Med."},{"issue":"12","key":"10.1016\/j.ygyno.2025.11.016_bb0070","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nrd1600","article-title":"Targeting protein kinases","volume":"3","author":"Melnikova","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.016_bb0075","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.ygyno.2025.11.016_bb0080","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","article-title":"MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens","volume":"15","author":"Li","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ygyno.2025.11.016_bb0085","series-title":"2023 ASCO Annual Meeting","article-title":"Initial efficacy and safety results from ENGOT-ov60\/GOG-3052\/RAMP 201: A phase 2 study of avutometinib (VS-6766) 6 defactinib in recurrent low-grade serous ovarian cancer (LGSOC)","author":"Banerjee","year":"2023"},{"key":"10.1016\/j.ygyno.2025.11.016_bb0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2024.01.028","article-title":"Preclinical efficacy of RAF\/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer","volume":"183","author":"McNamara","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.016_bb0095","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteom. Bioinformat."},{"issue":"29","key":"10.1016\/j.ygyno.2025.11.016_bb0100","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus Crizotinib in patients with advanced ALK-positive non-small cell lung Cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2025.11.016_bb0105","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2217\/fon-2021-1250","article-title":"Encorafenib plus binimetinib in patients with BRAF(V600)-mutant non-small cell lung cancer: phase II PHAROS study design","volume":"18","author":"Riely","year":"2022","journal-title":"Future Oncol."},{"issue":"36","key":"10.1016\/j.ygyno.2025.11.016_bb0110","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1200\/JCO.21.02659","article-title":"COLUMBUS 5-year update: a randomized, open-label, phase III trial of Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in patients with BRAF V600-mutant melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.016_bb0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol."},{"issue":"32","key":"10.1016\/j.ygyno.2025.11.016_bb0120","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: Binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2025.11.016_bb0125","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s11864-024-01205-4","article-title":"Targeted therapies in low-grade serous ovarian cancers","volume":"25","author":"Gonzalez","year":"2024","journal-title":"Curr. Treat. Options in Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.016_bb0130","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"A phase II, two-stage study of Letrozole and Abemaciclib in estrogen receptor-positive recurrent endometrial Cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2025.11.016_bb0135","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1158\/1535-7163.MCT-22-0004","article-title":"NOTCH signaling limits the response of low-grade serous ovarian cancers to MEK inhibition","volume":"21","author":"Llaurado Fernandez","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"19","key":"10.1016\/j.ygyno.2025.11.016_bb0140","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1158\/0008-5472.CAN-19-0244","article-title":"Src-dependent DBL family members drive resistance to Vemurafenib in human melanoma","volume":"79","author":"Feddersen","year":"2019","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.ygyno.2025.11.016_bb0145","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.016_bb0150","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/pcmr.12674","article-title":"BRAF internal deletions and resistance to BRAF\/MEK inhibitor therapy","volume":"31","author":"Johnson","year":"2018","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.016_bb0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.celrep.2016.05.064","article-title":"BRAF(V600E) kinase domain duplication identified in therapy-refractory melanoma patient-derived xenografts","volume":"16","author":"Kemper","year":"2016","journal-title":"Cell Rep."},{"issue":"7377","key":"10.1016\/j.ygyno.2025.11.016_bb0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.ygyno.2025.11.016_bb0165","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.016_bb0170","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10637-020-00975-6","article-title":"A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors","volume":"39","author":"Shapiro","year":"2021","journal-title":"Investig. New Drugs"},{"issue":"4","key":"10.1016\/j.ygyno.2025.11.016_bb0175","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/1078-0432.CCR-14-1814","article-title":"A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1\/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors","volume":"21","author":"Bedard","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.016_bb0180","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1634\/theoncologist.2019-0297","article-title":"Phase Ib study of combination therapy with MEK inhibitor Binimetinib and phosphatidylinositol 3-kinase inhibitor Buparlisib in patients with advanced solid tumors with RAS\/RAF alterations","volume":"25","author":"Bardia","year":"2020","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.016_bb0185","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2019.12.002","volume":"156","author":"Arend","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.11.016_bb0190","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s11523-017-0530-5","article-title":"A multi-arm phase I study of the PI3K\/mTOR inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus irinotecan or the MEK inhibitor PD-0325901 in advanced Cancer","volume":"12","author":"Wainberg","year":"2017","journal-title":"Target. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.016_bb0195","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10637-019-00776-6","article-title":"Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors","volume":"38","author":"Shapiro","year":"2020","journal-title":"Investig. New Drugs"},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.016_bb0200","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2019.11.029","article-title":"Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma","volume":"157","author":"Llaurado Fernandez","year":"2020","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582501100X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582501100X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:06:39Z","timestamp":1764943599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582501100X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"alternative-id":["S009082582501100X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.11.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}